logo-loader
viewhVIVO PLC

hVIVO hails Enanta Pharmaceuticals’ study success

The US drug developer used the UK company's London facility and its specially designed trial protocol

researcher filling testtube
Researchers were assessing the potential of a breakthrough drug to treat respiratory syncytial virus

A clinical study using facilities and a trial protocol developed by hVIVO PLC (LON:HVO) has delivered positive results.

Enanta Pharmaceuticals’ N-protein inhibitor, EDP-938, achieved a “highly statistically significant” reduction in viral load and cleared up the symptoms of respiratory syncytial virus (RSV).

RSV is an infection of the lungs and respiratory tract that commonly affects children.

In this particular clinical assessment healthy adults were intentionally infected in what’s called a challenge study that took place at specialist centre owned by hVIVO in London using a protocol developed by the company. A separate comparator group of people received a placebo treatment with no medical benefit.

Setting up the trial in this way, researchers were able to establish the potential efficacy of EDP-938.

“These positive clinical proof of concept results support the further development of EDP-938,” said hVIVO chairman, Dr Trevor Phillips.

“The study conducted by hVIVO highlights the value that can be obtained from challenge studies to rapidly establish clear indications of clinical efficacy and dose-response and deliver supporting safety data in a cost-effective controlled study at an early stage of a product's development.

“The data also further validate the value of our RSV challenge model that we believe to be the only such RSV model currently commercially available.”

In morning trading, hVIVO shares were 3.9% higher at 20.25p.

 -- Adds share price --

Quick facts: hVIVO PLC

Price: 11.625 GBX

LSE:HVO
Market: LSE
Market Cap: £9.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

on 19/9/19

2 min read